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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.01.001BACKGROUND AND OBJECTIVES: Despite the use of targeted therapy, chronic myelogenous leukemia (CML)
currently remains incurable with drug therapy, with patients requiring life-long treatment. Developing either a
vaccine to prevent the disease or another novel drug to specifically target and eradicate the CML cell will
require the identification of CML-associated cell-surface markers and molecules that can bind specifically to
the cell surface. In an attempt to discover peptides that bind specifically to cells in the early chronic phase
of the disease, we used phage-display technology to identify heptapeptides that bind specifically to the surface
of BCR/ABL-expressing fibroblasts.
METHODS: An in vitro system using NIH3T3 stably transfected with pGD210 (BCR/ABL) was used as a model
for the chronic phase of the disease. The cells were panned using a linear heptapeptide phage library (Ph.D 7.0)
in a negative/positive panning strategy with NIH3T3 containing only the plasmid vector as the wild type control.
RESULTS: We identified four novel peptides that were enriched through this technique. These peptides con-
tained either multiple proline residues or serine/threonine–proline pairs and showed a confirmed binding pref-
erence for BCR/ABL+ fibroblasts. The peptide Y-R-A-P-W-P-P also showed a binding affinity for granulocytes
from untreated CML patients.
CONCLUSION: We have identified several novel peptides that can be used in future studies to identify specific
CML cell-surface antigens or provide a novel drug-delivery mechanism.Although CML is one of the best describedleukemic diseases, the only deﬁnitive curecontinues to be bone marrow transplants.
Treatment with speciﬁc tyrosine kinase inhibitors
(TKI) offers a targeted therapy approach and is cur-
rently the standard of care for chronic phase CML,
yet in most cases life-long therapy is required to pre-
vent a relapse. In addition, despite remission being
rapidly achieved with TKI therapy in many patients,
some do not respond at all, suffer severe side-effects,
or acquire resistance mutations and relapse while on
therapy.1,2 Alternative therapies, including the devel-
opment of a CML vaccine3–5 and targeted drug-deliv-
ery mechanisms,6 both of which are based on the
concept of a unique CML or leukemic cell-surface
antigen, are thus currently being investigated.HeAlthough BCR/ABL, the novel fusion protein
responsible for chronic phase CML development,
can be processed and presented on the surface of clo-
nal cells, it is not highly immunogenic and has shown
limited success in vaccine trials with patients in the
chronic phase.7–9 Despite the use of global microarray
techniques10 and cancer/testis antigen proﬁling,11
CML cell-surface antigens remain poorly deﬁned. Re-
search is thus still ongoing to identify a CML-speciﬁc
antigen which holds potential for the development of
a vaccine and targeted drug-delivery.
Phage-display technology, using either peptide or
antibody libraries to identify ligands and receptors,
is a technique that is proving useful in the search
for cancer-speciﬁc markers.12–14 Despite the technical
difﬁculties associated with whole-cell panning (i.e.,matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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low level targets, suitable negative control cell types),
in the arena of haematological malignancies, this tech-
nique has already generated useful targets. This in-
cludes potentially new drug-delivery mechanisms in
acute myeloid leukemia (AML) and acute lympho-
blastic leukemia (ALL),6 identiﬁcation of growth
and proliferation modifying ligands in AML15 and
potential diagnostic markers for IFN-a sensitive
CML cells.16
In the search for a CML-speciﬁc antigen, we used
phage-display technology to identify peptides that
bind to the surface of BCR/ABL expressing cells, as
a means of identifying ligands that are associated spe-
ciﬁcally with chronic phase CML disease. Due to the
lack of suitable human cell-lines that represent
chronic phase disease and normal physiology, and
the difﬁculty associated with stable transfection of hu-
man haematopoietic stem cells,17 we chose to use a
BCR/ABL-expressing NIH3T3 mouse ﬁbroblast
cell-line as a model. Mouse and rat ﬁbroblast models
have been used extensively in deﬁning the pathogenic
role of BCR/ABL18–21 and allow for the development
of a well-controlled, genetically deﬁned system for the
whole-cell panning phage-display approach. We gen-
erated stably transfected clones using the pGD210
BCR/ABL expression vector,22 as well as a modiﬁed
vector-only control (pCVT). These cells were assessed
for cell-surface associated changes previously attrib-
uted to BCR/ABL expression and then panned
using a linear heptapeptide phage library in a nega-
tive/positive panning approach to identify peptides
that bind preferentially to BCR/ABL expressing
cells.MATERIALS AND METHODS
Stable clone generation
The BCR/ABL expression vector pGD210,22 (kindly
supplied by Prof G. Daley) was used to generate the
pCVT control plasmid, by excising the 7.2 kb bcr/
abl cDNA fragment with XhoI and re-ligating the vec-
tor. Endotoxin-free plasmid DNA (4 lg pGD210 and
2 lg pCVT) (Nucleobond Xtra EF, Macherey–Na-
gel) was used to transfect NIH3T3 mouse ﬁbroblasts
(2 · 106) using Nucleofector technology (LONZA,
program U-023). Transfected NIH3T3 were main-
tained in RPMI/10% FBS media (Gibco) and
400 lg/ml G418 (Promega) antibiotic selection was
started 48 h post-transfection for a 14-day period to
select transfected clones. Surviving clones were ex-
panded in the presence of G418, and cryopreserved
for later use.Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comBCR/ABL mRNA expression
Ribonucleic acid (RNA) was extracted using Total
RNA isolation reagent (TRIR) (ABgene) and the lev-
els of BCR/ABL mRNA expression were determined
using standardised methodology (1 lg RNA) for
minimal residual disease monitoring of this tran-
script,23–25 by the NHLS diagnostic service (Groote
Schuur Hospital, Cape Town).
Adherence independent growth
Agar clonogenic assay
Fibroblasts (3 · 105) were mixed with 3 ml 0.3%
agar/RPMI/10% FBS and plated on top of a solidi-
ﬁed layer of 0.6% agar/RPMI/10% FBS in six well
plates (Corning). Cells were incubated for 21 days
and colonies visualised using phase-contrast
microscopy.
Methylcellulose assay
Fibroblasts (5 · 103) were mixed with 100ul 1.5%
methylcellulose (Sigma–Aldrich) RPMI/10% FBS
media and plated into polyHEMA (Sigma–Aldrich)
coated 96-well plates. Following incubation for the
speciﬁed time periods, the colony expansion was mea-
sured by the addition of 20 ll CellTiter 96 AQueos
One reagent (Promega), incubation for 2 h at
37 C/5% CO2 and spectrophometry at 490 nM (An-
thos2001 plate reader). Triplicate blank readings were
subtracted.
In vitro cell motility assay
Conﬂuent cell layers were established in six well plates
in RPM1/10% FBS and a linear wound was created
by scratching through the monolayer using a sterile
200 ll pipette tip. To remove cell debris, the growth
medium was replaced and mitomycin C (10 lg/ml)
(Sigma–Aldrich) was added to prevent further cell
proliferation. Cells were incubated at 37 C/5%
CO2 and the wound width was measured at three ref-
erence points at 0 and 6 h post treatment using light
microscopy and the distance migrated recorded (lm).
Phage-display analysis
The phage-display linear heptapeptide library Ph.D
7.0 (New England Biosciences) with a complexity of
109 sequences, was used to pan NIH3T3 clones,
using a combination of negative/positive panning in
each round.26 Each panning round was performed
using cells at P3 post-thaw (to ensure similar mem-
brane composition) and both 3T3B.pGD210 and
3T3C.pCVT cells were of the same passage following
transfection. Cells (3 · 106) were plated in 10 cm
dishes, left to adhere O/N and then prewashed with33
34
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PBS/3% BSA at room temperature (RT) (20–22 C)
prior to panning. All planning stages were performed
at RT in PBS/3% BSA. Phages (2 · 1011) were pre-
incubated in 10 volumes PBS/3% for 1 h at 4 C
prior to each round of panning and then used to ﬁrst
pan the control cells (3T3C.pCVT) for 30 min at
RT. The supernatant was removed and used to nega-
tively pan a second set of 3T3C.pCVT cells for
30 min at RT. This phage-depleted supernatant was
used to positively pan against the BCR/ABL+ cells
(3T3B.pGD210) for 1 h at RT. Unbound/weakly
bound phage was removed with 10 PBS washes at
RT and cell-surface bound phage was eluted with
1 ml 0.2 M Glycine pH2.2/1 mg/ml BSA (15 min),
followed by neutralisation with 150 ll 1 M Tris pH
9.1. This eluted phage was ampliﬁed in ER2738 cells
and puriﬁed according to manufacturers’ recommen-
dations (NEB), with the extension of phage precipita-
tion to O/N at 4 C and phage collection of 45 min at
14,000 rpm at 4 C. This process was repeated for
four complete panning cycles. Post-panning, the
eluted phage-extract was also titred by plating on
LBtet XGal/ITPG agar plates and 10–30 separate
phage plaques were selected for sequence analysis
using the 96gII primer (NEB) (rounds 3 and 4).
Phage binding assay
Single phages were re-ampliﬁed, puriﬁed and titred,
and 1 · 1010 phages simultaneously panned against
1 · 106 3T3B.pGD210 and 3T3C.pCVT (plated in
6-well plates), K562 vs. HL60 cultured cells (2 ml
suspension cultures) or density-gradient prepared
granulocyte preparations from two healthy volunteers
and two untreated CML patients (2 ml suspension
cultures) (ethics approval REC REF:360/2006). All
cells were pre-washed in PBS/3%BSA and binding
was performed for 1 h at RT in PBS/3% BSA. The
cells were washed in PBS and the phages eluted with
Glycine/Tris treatment as described above. Phage
extractions were titred on LBtet XGal/ITPG agar
plates.RESULTS
Generation and characterisation of stable NIH3T3
BCR/ABL expressing clones
To control cell-surface changes associated with the
transfection methodology and the vector backbone
(i.e., gentamycin resistance), we modiﬁed the original
pGD210 BCR/ABL vector22 to create pCVT. This
vector lacks only the bcr/abl cDNA insert and was
a preferred control to untransfected cells in the
phage-display analysis. Three separate clones wereHeisolated and expanded following transfection with
either the BCR/ABL expression vector or the control
vector. The pGD210 clones expressed variable levels
of bcr/abl messenger RNA (mRNA) transcripts
(2.2 · 103–2.6 · 104) (Fig. 1A), while none of the
pCVT clones expressed this transcript. Although
the ratios of bcr/abl:abl transcripts (0.091–0.555)
did not approach 1, which is observed in BCR/ABL
positive CML cells (K562), a lower ratio (0.196)
was also shown in 3T3-MIG210, a BCR/ABL
expressing NIH3T3 cell-line which has been used
successfully in several BCR/ABL studies.27–29 Clone
3T3B.pDG210, which expressed the highest intracel-
lular bcr/abl:abl ratio of 1:2 (0.555) and shown to ex-
press the BCR/ABL protein via western hybridisation
analysis (results not shown), was chosen for character-
isation and phage-display analysis. Clone
3T3C.pCVT was used as the BCR/ABL negative
control in all further experiments.
To validate the use of the 3T3B.pDG210 cells as a
suitable model for phage-display analysis, these cells
were characterised for key features of BCR/ABL
expressing CML stem cells. One such feature is re-
duced cellular adherence to the stroma substrate,
which results in increased mobility and migration of
the cells. Additionally, these stem cells are capable
of anchorage-independent growth-signalling, which
leads to uncontrolled proliferation.19,30–34 These con-
sequences of BCR/ABL expression were of particular
interest as they involve both intracellular and cell-sur-
face protein alterations, with the latter being the main
target in phage-display analysis. The NIH3T3
pGD210 cells demonstrated a signiﬁcantly altered
adhesion phenotype compared to the control cells.
Agar clonogenic assays provided a qualitative assess-
ment of this phenotype, with 3T3B.pGD210 forming
large, round, suspended colonies when grown in the
dual-layer agar (21-day growth), compared to small
cell clusters of <10 cells in the controls (Fig. 1Bi).
Methylcellulose/polyHEMA suspension cultures al-
lowed for a quantitative analysis, and although colony
size was restricted compared to agar growth, the
majority of the 3T3B.pGD210 cells formed colonies
and clearly showed a growth advantage over the con-
trol in this adhesion-restricted environment
(Fig. 1Bii). A BCR/ABL-associated increase in mobil-
ity was demonstrated using the wound closure assay,
with 3T3B.pGD210 showing a 3.5-fold increased rate
of wound closure compared to the 3T3C.pCVT con-
trol (Fig. 1C). Combined, these results indicated that
the stable BCR/ABL+ mouse ﬁbroblasts showed
anchorage-independent growth and increased migra-
tion/mobility, key characteristics of BCR/ABLmatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Fig. 1. Characteristics of BCR/ABL+ NIH3T3 fibroblast clones. (A) BCR/ABL mRNA expression levels in 3T3.pGD210 clones and controls. B(i) Colony
formation in the double-layer agar clonogenic assay (21-day incubation). B(ii) Colony growth in methylcellulose media assayed by MTS conversion
(triplicate analysis). (C) In vitro motility assay indicating distance migrated over a 6-h period (4–6 scratches analysed).
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stem cells. These cells thus represented an appropriate
model to study the cell-surface effects of BCR/ABL
expression by phage-display.
Phage-display analysis of NIH3T3 BCR/ABL
clones
A phage-display library expressing linear heptapep-
tides was used to screen the ﬁbroblast cell-surface
for BCR/ABL-associated molecules in a whole-cell
panning approach. A combined negative/positive pan-
ning strategy was adopted, where phages were ﬁrst
hybridised against control ﬁbroblasts (3T3C.pCVT)
to remove phages that bind generally to ﬁbroblast
cell-surface molecules. This depleted phage pool was
then panned against the BCR/ABL+ cells
(3T3B.pGD210) to positively select bound phages,
which were harvested and re-ampliﬁed for the follow-
ing round.Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comThis panning strategy was performed in two inde-
pendent experiments, with 10 phages initially se-
quenced following three rounds of panning in each
experiment. Although no dominant motif was ob-
served, the combined analysis showed a predominance
of ligands containing proline, serine and threonine
residues, with 71% containing at least one proline res-
idue and 57% containing serine or threonine residues
(results not shown). Round 4 panning was performed
and 20/27 phages were sequenced respectively. No
signiﬁcant difference was observed between the two
experiments in terms of sequence dominance and thus
the 47 sequences were analysed collectively to look for
predominant motifs. Again, a similar enrichment of
phage peptides containing serine, threonine and pro-
line residues was observed (Fig. 2). The majority
(76%) of the peptides encoded at least one proline res-
idue, while as many as 36% encoded two or three.
One of the serine-rich ligands sequenced in round 335
Fig. 2. Alignment of phage-peptide sequences from 4 rounds of panning. Phage-peptide sequences showing an alignment of at least 3 residues to
one of the 5 enriched motifs are represented. PRO/SER/THR residues are highlighted to show their predominance and light grey blocks indicate
additional amino acid identity.
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T-S-Y), demonstrating a deﬁnite enrichment via this
methodology (Fig. 2). In total, four separate 7-mer
motifs were present in multiple copies following four
rounds of panning: I-P-T-L-P-S-S, S-S-P-S-T-S-Y,
A-H-K-M-G-T-P, Y-R-A-P-W-P-P. A 5-mer motif,
T-P-S-P-P, also showed some level of enrichment.
While 15/47 phages contained at least two amino
acids that agreed with this motif, no single phage-peptide
sequenced encoded all ﬁve amino acids (Fig. 2), whichHesuggested a fairly weak consensus motif. Overall, 47%
had at least 3/7 residues that matched the ﬁve motifs
described here, while 81% possessed two residues that
aligned. This indicated a progressive enrichment of
possible consensus ligand sequences. Unfortunately,
further panning rounds did not improve the motif
enrichment.
To conﬁrm the binding speciﬁcity of the peptide
motifs for BCR/ABL expressing cells, single phage
preparations, representing the ﬁve motifs, as well asmatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Fig. 3. Analysis of phage-binding preference to NIH3T3 transfected clones. Graphical representation of the number of specific phages bound to
either 3T3B.pGD210 or 3T3C.pCVT cells (triplicate analysis). The binding preference for BCR/ABL+ cells is indicated. Ctrl 1:H-W-G-M-W-S-Y; Ctrl 2:
N-D-I-N-N-Q-S. P = <0.01*, <0.001**.
PHAGE-DISPLAY TECHNOLOGY USE BCR/ABL EXPRESSING CELLS original research reporttwo unrelated control peptides (H-W-G-M-W-S-Y/
N-D-I-N-N-Q-S), were panned against 3T3B.pGD210
and control 3T3C.pCVT cells separately. Fig. 3 indi-
cates the number of phages remaining bound to the
two cell types following hybridisation and washing.
All four of the 7-mer motifs showed an increased bind-
ing preference for the BCR/ABL + ﬁbroblasts, with
Y-R-A-P-W-P-P motif showing the highest afﬁnity
with a sixfold increase in phage binding. The T-P-S-
P-X-X-X phage representing the T-P-S-P-P motif
showed no binding preference, but a much higher level
of binding to both cell types. This result may indicate a
ubiquitous, highly expressed epitope on mouse ﬁbro-
blasts; an increase in the number of negative panning
rounds would be needed to prevent the preferential
ampliﬁcation of this motif.
In addition to these phages showing a binding
preference in our ﬁbroblast model, a preliminary
experiment examining the clinical signiﬁcance of these
peptides also showed a binding preference for BCR/
ABL+ myeloid cells. Phages encoding the proline-rich
ligand Y-R-A-P-W-P-P and control H-W-G-M-W-
S-Y were hybridised against K562 (a blastic crisis
CML cell-line), HL60 (a promyelocytic BCR/ABL
negative cell-line), as well as granulocytes from two
healthy individuals, a chronic phase CML patient,
and a patient in accelerated phase CML (Fig. 4).
While the control phage showed no binding prefer-
ence to any cell type, the proline-rich ligand showed
a ﬁvefold increase in binding to cells representingHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comuntreated chronic phase CML, compared to control
cells. Cells which represented a more advanced disease
state, such as accelerated and blastic crisis phases,
showed a slightly lower, but still signiﬁcant increased
binding. This was demonstrated with a threefold in-
creased binding to BCR/ABL + K562 compared to
the HL60 control and a twofold increased binding
to the accelerated phase CML cells compared to
healthy granulocytes.DISCUSSION
In the search for alternative strategies for CML treat-
ment, vaccines and target drug-delivery systems are
actively being investigated. For these kinds of thera-
pies to be effective, it is necessary to identify antigens
where expression is speciﬁcally linked to diseased cells,
with preference being for a protein associated with
early chronic phase disease. To further the identiﬁca-
tion of such an antigen, we investigated the direct ef-
fects of BCR/ABL expression, the primary oncogene
in CML development, on cell-surface changes in a
ﬁbroblast model of disease. Through the use of
phage-display technology with a linear heptapeptide
library, we aimed to identify ligands that bound spe-
ciﬁcally to BCR/ABL+ cells, which could then be
used in future studies to characterise the associated
cell-surface antigen or be investigated as a novel
drug-delivery mechanism.37
Fig. 4. Analysis of phage-binding preference to BCR/ABL+ myeloid cells. Graphical representation of the number of specific phages bound to
granulocyte and cell-line preparations (duplicate analysis). The binding preference for BCR/ABL+ cells is indicated. Ctrl: H-W-G-M-W-S-Y; CML1:
chronic-phase CML patient, CML2: accelerated-phase CML patient, K562: BCR/ABL+ blastic crisis cell-line, HL60:BCR/ABL myeloid cell line.
P = 0.01*, <0.005**.
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ing ﬁbroblasts generated a number of lead sequences
which showed a preference for binding to BCR/
ABL+ cells: I-P-T-L-P-S-S, Y-R-A-P-W-P-P, S-S-
P-S-T-S-Y and A-H-K-M-G-T-P. All four enriched
ligands contained proline residues, but more speciﬁ-
cally contained either multiple proline residues or
SER/THR-PRO motifs. Proline-rich ligands are of-
ten associated with signalling proteins that have
WW and SRC-homology domains (SH2 and SH3)
and include many proteins involved in responses to
extracellular signals and cytoskeletal rearrangements
(i.e., ABL and actin-binding proteins).35,36 Both the
I-P-T-L-P-S-S and Y-R-A-P-W-P-P ligands, en-
riched in this study, speciﬁcally have the core P-x-x-
P motif that is recognised by proteins with a SH3
domain.35 Due to the formation of a hydrophobic
binding surface, proline-rich ligands generally do not
bind tightly to signalling protein domains, but this al-
lows for a rapid on/off signalling mechanism.36 The
relatively low binding preference of these ligands (four
and sixfold respectively) for BCR/ABL+ ﬁbroblasts
observed in our study may thus represent a signiﬁcant
ﬁnding.
The SER/THR-PRO motif is common in ligands
binding to proline-directed protein kinases such as cy-
clin-dependant kinases, kinases containing class IVHeWW or polo-box domains, and mitotic phosphopro-
teins. These proteins are crucial in cell-cycle regula-
tion/proliferation, and signalling via these proteins
is often aberrant in cancer.37,38 Proline-directed ki-
nases, such as Pin1, transduce a signal by cleaving
the SER/THR-PRO bond present in a ligand, which
results in several pathways, including mitotic division
and microtubule formation, being activated.37 Revers-
ible phosphorylation of the serine/threonine residue
in this motif is an important control mechanism, as
it alters the binding efﬁciency of the ligand and can
allow for rapid signalling changes. The S-S-P-S-T-
S-Y peptide enriched in our study potentially pos-
sesses the key signalling motif S-pS/pT-P-x of the
polo-box domain, while the pS/pT-P motif of the
class IV WW domain may be found in the A-H-K-
M-G-T-P peptide. Due to the phosphorylation of
these ligands playing a role in ligand binding efﬁ-
ciency, the lower binding preference observed for
these ligands may be due to the lack of phosphoryla-
tion of these residues in this in vitro system.
Phage-display analysis of BCR/ABL+ mouse ﬁbro-
blasts has generated several interesting and relevant
lead ligands that may be of use in either deﬁning
the cell-surface antigens speciﬁc to chronic phase
CML, or by providing tools for targeted drug-delivery.
The peptides deﬁned in this study contain motifs thatmatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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are often linked to ligands associated with proteins in-
volved in cell-cycle regulation and cytoskeletal rear-
rangements, hallmark characteristics of BCR/ABL
positive cells in vivo. Previous phage-display analysis
on CML patients and cell-lines has concentrated on
the blastic crisis stage of the disease, a complex disease
stage characterised by many varied secondary genetic
mutations.6,15 In these studies, proline-rich ligands
were not found to be enriched, indicating that the no-
vel ligands identiﬁed in our study may represent
markers that are speciﬁc to the chronic phase of the
disease (BCR/ABL speciﬁc). Promising results from
a preliminary evaluation of peptide-binding to mye-
loid cells from CML patients, cell-lines and controls,
indicated that the proline-rich peptide tested showed
a binding preference for BCR/ABL+ myeloid cells
and a higher preference for chronic phase cells, which
supports our hypothesis. Future studies would in-
clude the binding potential of puriﬁed peptides to var-
ious cell populations in a larger chronic phase CML
patient cohort, isolation of the membrane-boundHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comreceptor and internalisation potential of the ligands
for drug-delivery.FUNDING SOURCE
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